Quidelortho Corporation · NASDAQ:QDEL

Quidelortho — Quidel — Raymond James 43rd Annual Institutional Investors Conference (March 2022)

13 slides from Quidelortho's conference presentation, Mar 9, 2022

1. Slide 1: Quidel Corporation – Raymond James, March 2022

   Quidel Corporation Raymond James March 2022 Copyright © 2022 Quidel Corporation. All rights reserved.

2. Slide 2: Forward-Looking Statements and Additional Information

   Forward-Looking Statements and Additional Information Where You Can Find Additional Information In connection with the proposed business combination transaction among Quidel Corporation (the “Company”), Ortho Clinical Diagnostics Holdings plc (“Ortho”) and Coronado Topco, Inc. (“Topco”), Topco has f

3. Slide 3: Committed to delivering strong performance by investing in growth and innovation

   1979 – 1989 1989 – 2009 • Company founded • Launched QuickVue Influenza A/B rapid diagnostic assay • Primarily a provider of Strep A and Pregnancy rapid diagnostics • First company to receive CLIA waiver for Flu, Strep and H. pylori tests 2009 – Present M&A: Product Launches: • • Committed to Signed

4. Slide 4: As a standalone, Quidel has been successful in executing on opportunities

   Quidel’s first transformative event: acquisition of Alere assets, effectively doubling the size & revenue profile • Successfully integrated the Triage and Beckman businesses • Established global infrastructure and commercial teams • Reduced leverage from 4.2X to < 1.0X within 2 years* • Harvested $2

5. Slide 5: Ortho represents our third transformative opportunity and a very attractive transaction

   Ortho represents our third transformative opportunity and a very attractive transaction • Innovative solutions spanning the diagnostics continuum – high- $50B Definitive volume to rapid point-of-care and home use Combined Market Leadership • Multiple modalities to address increasingly diverse clinic

6. Slide 6: Transaction overview

   Transaction overview • Quidel to acquire Ortho for $24.68 per share of common stock as of December 22, 2021, funded through a combination of cash and newly issued shares in the combined company Transaction • Ortho shareholders will receive $7.14 per common share and 0.1055 shares of common stock in

7. Slide 7: Compelling Pro Forma Financial Outlook

   Compelling Pro Forma Financial Outlook Pro forma combination is expected to create significant shareholder value (1) Pro Forma Addressable Market $23bn+ $50bn+ Opportunity Long-Term Revenue Growth 17% CAGR 9-11% CAGR Outlook EBITDA Mid 30% >30% Margin(2) -- Accretive to cash EPS within 12 EPS months

8. Slide 8: A leading Top-7 IVD pure-play

   A leading Top-7 IVD pure-play FY 2020 IVD Revenue ($ in millions) (1) $15,431 (1) $10,805 Top-7 (1) $7,403 Diagnostics Player (2) $5,343 (1) $4,989 $3,809 100,000+ Quidel Pro Forma $3,428 Instrument Installed Base $2,728 Across All Platforms (1) $2,500 (1) $2,068 130+ $1,766 $1,662 Countries (3) $1,

9. Slide 9: Together, we will be one of the largest pure play Dx companies

   Together, we will be one of the largest pure play Dx companies. Able to leverage R&D, Clin/Reg, Commercial expertise to solidify leadership position and drive growth into new markets • Global infrastructure (NA, LATAM, EMEA, Japan, China, • Sizeable growth opportunities in fast growing segments ASPA

10. Slide 10: Dedicated integration team focused on achieving clear milestones

    Dedicated integration team focused on achieving clear milestones Process allows the rest of the organization to continue running and growing the businesses Executive Steering Committee Integration Management Team Close the Deal & Integrate the Capture Synergies Prepare for Integration Organization N

11. Slide 11: Savanna's differentiators include cost advantage, panel size and TAT

    Savanna’s differentiators include cost advantage, panel size and TAT System has strong appeal in Ortho’s small-to-medium sized hospital customers Multiplexing technology provides quick 1 diagnosis in one sample • Magnetic bead based nucleic acid isolation • 4 color PCR multiplexing for up to 12 anal

12. Slide 12: Key Takeaways

    Key Takeaways Continue driving momentum in core businesses and leverage strengths of both companies Unrelenting focus on commercial excellence while expanding into new geographies and markets Drive the global commercial execution of Savanna Integrate the organizations while maintaining the culture a

13. Slide 13: a) |

    a) |

Quidel — Raymond James 43rd Annual Institutional Investors Conference (March 2022) on 6ix